Aurobindo Pharma USA Secures FTC Clearance for $250 Million Lannett Acquisition

FTC clearance for Aurobindo Pharma USA's $250 million acquisition of Lannett Company removes the last major regulatory hurdle before post-merger integration begins, and puts GMP harmonisation squarely on the agenda for plant heads overseeing the combined U.S. manufacturing network.

The transaction adds a U.S.-based solid-dose manufacturing facility to Aurobindo USA's existing footprint, extending its domestic generics portfolio without the lead time of a greenfield build. For QA directors, the immediate priority is a gap assessment between Lannett's incumbent quality systems and Aurobindo's established ICH Q10-aligned pharmaceutical quality system, a process that typically precedes any consolidated site master file submission to FDA.

Regulatory affairs leads should note that FTC scrutiny of generics consolidation has intensified over recent cycles; clearance here signals the combined entity's product overlap did not trigger divestiture conditions, but ongoing 21 CFR Part 211 compliance obligations transfer in full to Aurobindo USA from the date of close. Any open observations or commitments on Lannett's facility carry forward and will require documented resolution under the acquirer's CAPA framework.

From a supply-chain standpoint, the addition of domestic manufacturing capacity is directly relevant to current FDA priorities around U.S. drug supply resilience, particularly for generic solid-dose products where single-source concentration remains a watch item for agency reviewers.

Process validation status across Lannett's transferred product lines will be an early integration checkpoint, with sterility assurance protocols and annual product review cycles requiring alignment before any post-merger site inspection.

Source: Media4Growth via Indian Pharma Post, 21 June 2026.